Education and Training
Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial
The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Continuous glucose monitoring device
Eligibility
Inclusion Criteria:
- 1. Patients with T1DM or T2DM diagnosed for at least 6 months. 2. Individual is 18-80
years old, inclusive, at the time of screening. 3. Must be and have been in stable
treatment regimen for at least 1 month with a multiple daily insulin dosing regimen
(at least two insulin doses with meals daily) or CSII using at least two bolus doses a
day with meals, irrespective of delivery device(s).
Exclusion Criteria:
- 1. History of skin adhesive tolerance issues in the area of sensor placement. 2. HbA1c
> 9%. 3. Insulin meal dosing based on fixed dose regimens. 4. Absence of established
correction factor for high glucose. 5. Hematocrit below 10% under the lower limit of
the normal range. 6. Body mass index < 18.5 kg/m2. 7. Inadequate intravenous access on
arms. 8. Participant has had a hypoglycemic seizure within the past 6 months prior to
enrollment.
9. Participant has had an episode of diabetic ketoacidosis (DKA) within the past 6
months prior to enrollment.
10. Participant has a history of a seizure disorder. 11. Pregnancy, planned pregnancy
within the study period, or unwillingness to use reliable contraception during the
study period.
12. Planned MRI, CT scan or diathermia procedure for the duration of the study.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting